EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis

Seth Inzaule, Philippa Easterbrook, Ashley Latona, Nathan P Ford, William Irving, Philippa C Matthews, Marco Vitoria, Chris Duncombe, Amalia Giron, Suzanne McCluskey, Olufunmilayo Lesi, Serge Tchamgoue und 5 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae431 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Seth Inzaule und 16 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam Institute for Global Health and Development, and Department of Global Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Nether…. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Resistance, Viral, Hepacivirus, Hepatitis C, Chronic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The advent of short-course, curative treatment with direct-acting antivirals (DAA) has given promise for the global elimination of hepatitis C virus (HCV) infections by 2030. Virological failure occurs in 2%–12% of persons receiving curative DAA treatment and may be presaged by pre-existing polymorphisms or result from selection of drug resistant variants during therapy.

Methods

We conducted a systematic review to assess the prevalence of HCV resistance associated substitutions (RAS) among individuals with chronic hepatitis C infection who had virological failure following initial or re-treatment with pan-genotypic DAA regimens. We included 34 and 22 studies assessing RAS in people with virological failure published between January 2014 and July 2023. Pooled RAS prevalence was estimated using random-effects meta-analysis.

Results

The pooled prevalence of RAS in people with virological failure following initial DAA treatment was 78.0% (95% confidence interval [CI]: 62.0–92.0) for sofosbuvir/velpatasvir, 81.0% (95% CI: 67.0–93.0) for sofosbuvir/daclatasvir, and 79.0% (95% CI: 70.0–87.0) for glecaprevir/pibrentasvir, with a high prevalence of resistance to the NS5A inhibitors. Among those with virological failure following re-treatment regimens, RAS were present in 93.0% (95% CI: 83.0–99.0) for sofosbuvir/velpatasvir/voxilepravir and in 100% (95% CI: 92.0–100) for glecaprevir/pibrentasvir, with resistance driven by RAS to NS5A inhibitors.

Discussion

At least 1 RAS is present in a high proportion of the few individuals with virological failure following initial or re-treatment with pan-genotypic DAA regimens. There is a need for ongoing surveillance for DAA-associated resistance, to assess risk factors for their development and clinical impact to inform best practice strategies for re-treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDrug Resistance, ViralHepacivirusHepatitis C, ChronicTreatment FailureHumansGenotypePrevalenceSustained Virologic Response

Stichwörter der Autor:innen

chronic hepatitis C virusinitial treatment and retreatmentpan-genotypic direct acting agentsresistance-associated substitutionstreatment failure

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Amsterdam Institute for Global Health and Development, and Department of Global Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • HIV, Hepatitis and Sexually Transmitted Infection Department, World Health Organization, Geneva, Switzerland.
  • Division of Geographic Medicine and Infectious Diseases,Tufts University School of Medicine, Boston, Massachusetts, USA.
  • School of Life Sciences, Division of Microbiology and Infectious Diseases, The University of Nottingham, Nottingham, United Kingdom.
  • The Francis Crick Institute, London, United Kingdom.
  • International Association of Providers of AIDS Care, Washington, DC, USA.

Förderung

  • World Health Organization

Zitieren

APA

Inzaule, S., Easterbrook, P., Latona, A., Ford, N. P., Irving, W., Matthews, P. C., Vitoria, M., Duncombe, C., Giron, A., McCluskey, S., Lesi, O., Tchamgoue, S., Halford, R., Adda, D., Thomson, E., Dusheiko, G., & Jordan, M. R. (2024). Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae431

Vancouver

Inzaule S, Easterbrook P, Latona A, Ford NP, Irving W, Matthews PC, et al. Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae431

BibTeX
@article{Inzaule2024,
  author = {Inzaule, Seth and Easterbrook, Philippa and Latona, Ashley and Ford, Nathan P and Irving, William and Matthews, Philippa C and Vitoria, Marco and Duncombe, Chris and Giron, Amalia and McCluskey, Suzanne and Lesi, Olufunmilayo and Tchamgoue, Serge and Halford, Rachel and Adda, Danjuma and Thomson, Emma and Dusheiko, Geoff and Jordan, Michael R},
  title = {Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae431}
}
Kostenlos starten →